Clinical effects of dapagliflozin in patients with type 2 diabetes mellitus and paroxysmal atrial fibrillation
- Authors: Bagriy A.E1, Prikolota O.A1, Prikolota A.V.1, Mikhailichenko E.S1, Golodnikov I.A1, Bagriy O.N2, Kotova K.A1
-
Affiliations:
- M. Gorky Donetsk National Medical University
- Donetsk Regional Clinical Territorial Medical Association
- Issue: Vol 29, No 11/12 (2022)
- Pages: 47-52
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321103
- DOI: https://doi.org/10.18565/pharmateca.2022.11-12.47-52
- ID: 321103
Cite item
Abstract
Full Text
About the authors
A. E Bagriy
M. Gorky Donetsk National Medical UniversityDonetsk, DPR
O. A Prikolota
M. Gorky Donetsk National Medical UniversityDonetsk, DPR
Alina V. Prikolota
M. Gorky Donetsk National Medical University
Email: prikav@yandex.ru
Cand. Sci. (Med.), Teaching Assistant at the Department of Therapy, FIPO n.a. professor A.I. Dyadyk Donetsk, DPR
E. S Mikhailichenko
M. Gorky Donetsk National Medical UniversityDonetsk, DPR
I. A Golodnikov
M. Gorky Donetsk National Medical UniversityDonetsk, DPR
O. N Bagriy
Donetsk Regional Clinical Territorial Medical AssociationDonetsk, DPR
K. A Kotova
M. Gorky Donetsk National Medical UniversityDonetsk, DPR
References
- American Diabetes Association. Cardiovasculardisease and risk management: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(S1):S111-S134. doi: 10.2337/dc20-s010.
- Cosentino F, Aboyans V., Bailey C.J., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J.2020;41 (2):255-323. Doi: 10.1093/ eurheartj/ehz486.
- Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Сахарный диабет 2 типа у взрослых: клинические рекомендации. Сахарный диабет.2020;23(S2):4-102.
- Cosentino F, Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J.2019;00:1-69.
- Wang A., Green J.B., Halperin J.L., et al. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. JAAC.2019;74(8):1107-15. doi: 10.1016/j.jacc.2019.07.020.
- Hindricks G., Potpara T, Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J.2020;42:373-498. doi: 10.1093/eurheartj/ehaa612.
- McMurray J.J.V, DeMets D.L., inzucchi S.E. et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21(5):665-75. Doi: 10.1002/ ejhf.1432.
- Solomon S.D., Jhund PS., Claggett B.L., et al. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril. Valsartan: The DAPA-HF Trial. JACC Heart Fail.2020;8(10):811-18. Doi: 10.1016/j. jchf.2020.04.008.
- Butt J.H., Docherty K.F, Jhund PS., et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail. 2022;24(3):513-25. doi: 10.1002/ejhf.2381.
- Newman J.D., Schwartzbard A.Z., Weintraub H.S., et al. Primary prevention of cardiovascular disease in diabetes mellitus. JACC. 2017;70(7):883-93. doi: 10.1016/j.jacc.2017.07.001.
- Zelniker T.A., Bonaca M.P, Furtado R.H.M., et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 2020;141:1227-34. Doi: 10.1161/ CiRCULATiONAHA.119.044183.
- Pathak R.K., Middeldorp M.E., Meredith M., et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: a Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015;65:2159-69. Doi: 10.1016/j. jacc.2015.03.002.
- Sjstrm C.D., Johansson P, Ptaszynska A., et al. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab. Vasc. Dis. Res.2015;12(5):352-58. doi: 10.1177/1479164115585298.
- List J.F, Woo V, Morales E., et al. Sodium-dependent cotransport inhibitor with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650-57. doi: 10.2337/dc08-1863.
- Arnett D.K., Blumenthal R.S., AlbertM.A. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology. American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:596-646. Doi: 10.1161/ CiR.0000000000000678.